The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected ... Moving checkpoint inhibitors further up the treatment pathway into earlier adjuvant and neoadjuvant ...
Libtayo is also under review by the EMA as a treatment for treatment-naïve NSCLC patients with PD-L1 expression of at least 50%, with a decision expected in the second quarter of 2021, according ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab ... has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell ...
The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback